Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: A randomized controlled clinical trial

Joanne M. Langley; Louise Frenette; Robert Jeanfreau; Scott A. Halperin; Michael Kyle; Laurence Chu; Shelly McNeil; Mamadou Dramé; Philippe Moris; Louis Fries; David W. Vaughn

doi:10.1016/j.vaccine.2014.11.018

Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: A randomized controlled clinical trial

Joanne M. Langley, Louise Frenette, Robert Jeanfreau, Scott A. Halperin, Michael Kyle, Laurence Chu, Shelly McNeil, Mamadou Dramé, Philippe Moris, Louis Fries, David W. Vaughn

科研成果: 期刊稿件 › 文章 › 同行评审

14 引用（Scopus）

源语言	英语
页（从-至）	559-567
页数	9
期刊	Vaccine
卷	33
期	4
DOI	https://doi.org/10.1016/j.vaccine.2014.11.018
出版状态	已出版 - 1月 15 2015

!!!ASJC Scopus Subject Areas

分子药学
一般免疫学和微生物学
一般兽医学
公共卫生、环境和职业健康
传染病学

联合国可持续发展目标

此成果有助于实现下列可持续发展目标：

访问文件

10.1016/j.vaccine.2014.11.018

其它文件与链接

引用此

Langley, J. M., Frenette, L., Jeanfreau, R., Halperin, S. A., Kyle, M., Chu, L., McNeil, S., Dramé, M., Moris, P., Fries, L., & Vaughn, D. W. (2015). Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: A randomized controlled clinical trial. Vaccine, 33(4), 559-567. https://doi.org/10.1016/j.vaccine.2014.11.018

Langley, JM, Frenette, L, Jeanfreau, R, Halperin, SA, Kyle, M, Chu, L, McNeil, S, Dramé, M, Moris, P, Fries, L & Vaughn, DW 2015, 'Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: A randomized controlled clinical trial', Vaccine, 卷 33, 号码 4, 页码 559-567. https://doi.org/10.1016/j.vaccine.2014.11.018

@article{83f87a4c6c9047a097988c547f6e75f5,

title = "Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: A randomized controlled clinical trial",

author = "Langley, {Joanne M.} and Louise Frenette and Robert Jeanfreau and Halperin, {Scott A.} and Michael Kyle and Laurence Chu and Shelly McNeil and Mamadou Dram{\'e} and Philippe Moris and Louis Fries and Vaughn, {David W.}",

note = "Funding Information: The study was funded by GlaxoSmithKline Biologicals SA and the Biomedical Advanced Research and Development Authority (BARDA) grant number HHSO100200700029C, United States Department of Health and Human Services. GlaxoSmithKline Biologicals SA was involved in all stages of the study conduct and analysis. GlaxoSmithKline Biologicals SA also took in charge all costs associated with the development and the publishing of the present manuscript. All authors had full access to the data. The corresponding author had final responsibility to submit for publication. Publisher Copyright: {\textcopyright} 2014 The Authors.",

year = "2015",

month = jan,

day = "15",

doi = "10.1016/j.vaccine.2014.11.018",

language = "English",

volume = "33",

pages = "559--567",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "4",

}

TY - JOUR

T1 - Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults

T2 - A randomized controlled clinical trial

AU - Langley, Joanne M.

AU - Frenette, Louise

AU - Jeanfreau, Robert

AU - Halperin, Scott A.

AU - Kyle, Michael

AU - Chu, Laurence

AU - McNeil, Shelly

AU - Dramé, Mamadou

AU - Moris, Philippe

AU - Fries, Louis

AU - Vaughn, David W.

N1 - Funding Information: The study was funded by GlaxoSmithKline Biologicals SA and the Biomedical Advanced Research and Development Authority (BARDA) grant number HHSO100200700029C, United States Department of Health and Human Services. GlaxoSmithKline Biologicals SA was involved in all stages of the study conduct and analysis. GlaxoSmithKline Biologicals SA also took in charge all costs associated with the development and the publishing of the present manuscript. All authors had full access to the data. The corresponding author had final responsibility to submit for publication. Publisher Copyright: © 2014 The Authors.

PY - 2015/1/15

Y1 - 2015/1/15

UR - http://www.scopus.com/inward/record.url?scp=84920604106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920604106&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2014.11.018

DO - 10.1016/j.vaccine.2014.11.018

M3 - Article

C2 - 25448092

AN - SCOPUS:84920604106

SN - 0264-410X

VL - 33

SP - 559

EP - 567

JO - Vaccine

JF - Vaccine

IS - 4

ER -

Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: A randomized controlled clinical trial

!!!ASJC Scopus Subject Areas

联合国可持续发展目标

访问文件

其它文件与链接

指纹

引用此